Table V.
Summary of experimental studies investigating effects of analgesic exposure in human fetal testis tissue.
| Model and regimen | Results | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposure | Model | Fetal age (weeks) | Dose | Route | Regimen | Supplemented | Testosterone | AMH | INSL3 | Germ Cells | Study | Comments |
| Paracetamol | In-vitro | 8–11 | 10−5 M | Media | 7d | Nil | ↓ | Hurtado-Gonzalez et al. (2018) | ||||
| In-vitro | 8–12 | 10−5 M | Media | 24–72 h | hCG | ↔ | ↓* | ↔ | Mazaud-Guittot et al. (2013) | *Dose response ↓ | ||
| In-vitro | 10–12 | 10−5 to 10−4 M | Media | 72 h | hCG | ↔ | Gaudriault et al. (2017) | |||||
| In-vitro | 10–12 | 10−8 to 10−6 M | Media | 72 h | hCG | ↑ (25%) | Gaudriault et al. (2017) | |||||
| Xenograft | 14–20 | 60 mg/kg/d | Oral Gavage | 7d | hCG | ↓ | van den Driesche et al. (2015a) | |||||
| Xenograft | 14–20 | 60 mg/kg/d | Oral Gavage | 7d | hCG | ↓ | Hurtado-Gonzalez et al. (2018) | |||||
| Xenograft | 14–20 | 60 mg/kg/d | Oral Gavage | 1d | hCG | ↔ | van den Driesche et al. (2015a) | |||||
| Xenograft | 14–20 | 60 mg/kg/d | Oral Gavage | 1d | hCG | ↓ | Hurtado-Gonzalez et al. (2018) | |||||
| Ibuprofen | Xenograft | 14–17 | 60 mg/kg/d | Oral Gavage | 7d | hCG | ↔ | ↔ | Ben Mamaar (2017) | |||
| Xenograft | 14–20 | 60 mg/kg/d | Oral Gavage | 1d | hCG | ↓ | Hurtado-Gonzalez et al. (2018) | |||||
| Xenograft | 14–20 | 60 mg/kg/d | Oral Gavage | 7d | hCG | ↓ | Hurtado-Gonzalez et al. (2018) | |||||
| In-vitro | 7–8 | 10−5 M | Media | 72 h | hCG | ↔ | ↓ | Ben Mamaar (2017) | ||||
| In-vitro | 8–10 | 10−5 to 10−4 M | Media | 72 h | hCG | ↓ | ↓ | ↔ | ↔ | Ben Mamaar (2017) | ||
| In-vitro | 8–10 | 10−7 to 10−6 M | Media | 72 h | hCG | ↔ | ↓** | ↔ | Ben Mamaar (2017) | **10−7 only | ||
| In-vitro | 8–11 | 10−5 M | Media | 7d | Nil | ↓*** | Hurtado-Gonzalez et al. (2018) | ***Gonocytes only | ||||
| In-vitro | 10–12 | 10−7 to 10−4 M | Media | 24–72 h | hCG | ↔ | ↔* | ↔* | Ben Mamaar (2017) | *Dose response ↓ | ||
| In-vitro | 10–12 | 10−8 to 10−5 M | Media | 72 h | hCG | ↔ | Gaudriault et al. (2017) | |||||
| In-vitro | 10–12 | 10−4 M | Media | 72 h | hCG | ↑ | Gaudriault et al. (2017) | |||||
| Aspirin | In-vitro | 8–10 | 10−7 M | Media | 72 h | hCG | ↔ | Mazaud-Guittot et al. (2013) | ||||
| In-vitro | 8–10 | 10−6 to 10−4 M | Media | 72 h | hCG | ↑ | ↑# | ↔ | Mazaud-Guittot et al. (2013) | #Only tested at 10−5 (8–12 GW) | ||
| In-vitro | 10–12 | 10−7 to 10−4 M | Media | 72 h | hCG | ↔ | ↔## | Mazaud-Guittot et al. (2013) | ##Only tested at 10−5 | |||
| In-vitro | 10–12 | 10−8 to 10−4 M | Media | 72 h | hCG | ↔ | Gaudriault et al. (2017) | |||||
| Indomethacin | In-vitro | 8–12 | 10−5 M | Media | 72 h | hCG | ↑ (20%) | ↔### | ↔ | Mazaud-Guittot et al. (2013) | ###(10–12 GW) | |
| In-vitro | 10–12 | 10−8 to 10−5 M | Media | 72 h | hCG | ↔ | Gaudriault et al. (2017) | |||||
| In-vitro | 10–12 | 10−4 M | Media | 72 h | hCG | ↑ (20%) | Gaudriault et al. (2017) | |||||
| Aniline | In-vitro | 10–12 | 10−8 to 10−5 M | Media | 96 h | hCG | ↔#### | Gaudriault et al. (2017) | ####↓ 20% (10−7) | |||
Significant effects associated with adverse outcomes are highlighted in red, no change or significant effects not expected to result in adverse outcomes are highlighted in green.